JP2024528967A5 - - Google Patents
Info
- Publication number
- JP2024528967A5 JP2024528967A5 JP2024506528A JP2024506528A JP2024528967A5 JP 2024528967 A5 JP2024528967 A5 JP 2024528967A5 JP 2024506528 A JP2024506528 A JP 2024506528A JP 2024506528 A JP2024506528 A JP 2024506528A JP 2024528967 A5 JP2024528967 A5 JP 2024528967A5
- Authority
- JP
- Japan
- Prior art keywords
- cpf1
- population
- grna
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228509P | 2021-08-02 | 2021-08-02 | |
| US63/228,509 | 2021-08-02 | ||
| US202163278899P | 2021-11-12 | 2021-11-12 | |
| US63/278,899 | 2021-11-12 | ||
| PCT/US2022/039192 WO2023014727A1 (en) | 2021-08-02 | 2022-08-02 | Systems and methods for the treatment of hemoglobinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528967A JP2024528967A (ja) | 2024-08-01 |
| JP2024528967A5 true JP2024528967A5 (enExample) | 2025-08-08 |
Family
ID=83050049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506528A Pending JP2024528967A (ja) | 2021-08-02 | 2022-08-02 | ヘモグロビン異常症の治療のためのシステム及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335476A1 (enExample) |
| EP (1) | EP4381068A1 (enExample) |
| JP (1) | JP2024528967A (enExample) |
| KR (1) | KR20240043772A (enExample) |
| AU (1) | AU2022325054A1 (enExample) |
| CA (1) | CA3226886A1 (enExample) |
| WO (1) | WO2023014727A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4630554A1 (en) * | 2022-12-05 | 2025-10-15 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2026027887A2 (en) * | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| ES2745769T3 (es) | 2014-03-10 | 2020-03-03 | Editas Medicine Inc | Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10) |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| KR102907245B1 (ko) * | 2018-03-14 | 2026-01-05 | 에디타스 메디신, 인코포레이티드 | 혈색소병증 치료를 위한 시스템 및 방법 |
| EP4069829A1 (en) | 2019-12-08 | 2022-10-12 | Editas Medicine, Inc. | Modified cells and methods for the treatment of hemoglobinopathies |
-
2022
- 2022-08-02 JP JP2024506528A patent/JP2024528967A/ja active Pending
- 2022-08-02 EP EP22758343.2A patent/EP4381068A1/en active Pending
- 2022-08-02 CA CA3226886A patent/CA3226886A1/en active Pending
- 2022-08-02 WO PCT/US2022/039192 patent/WO2023014727A1/en not_active Ceased
- 2022-08-02 KR KR1020247006536A patent/KR20240043772A/ko active Pending
- 2022-08-02 US US18/294,995 patent/US20240335476A1/en active Pending
- 2022-08-02 AU AU2022325054A patent/AU2022325054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12037602B2 (en) | Methods and compositions for modulating a genome | |
| JP7761294B2 (ja) | 遺伝子編集における非意図的な変異の阻害 | |
| JP2025081309A5 (enExample) | ||
| EP4100032B1 (en) | Gene editing methods for treating spinal muscular atrophy | |
| US20230242899A1 (en) | Methods and compositions for modulating a genome | |
| JP2021518102A5 (enExample) | ||
| CA3224970A1 (en) | Compositions and methods for efficient genome editing | |
| US20240401018A1 (en) | Evolved double-stranded dna deaminase base editors and methods of use | |
| JPH06502311A (ja) | Ｒｎａ療法を提供するためのｄｎａ構造 | |
| US20250340854A1 (en) | ENGINEERED Cas12f PROTEIN | |
| EP2838912A1 (en) | Peptides for the binding of nucleotide targets | |
| US20230374476A1 (en) | Prime editor system for in vivo genome editing | |
| JP2024501246A5 (enExample) | ||
| JP2024528967A5 (enExample) | ||
| TW202421785A (zh) | 用於ｈｂｖ基因表現之表觀遺傳調節之組合物及方法 | |
| US20250312376A1 (en) | Compositions and methods for modulating a genome in t cells, induced pluripotent stem cells, and respiratory epithelial cells | |
| CN117683749B (zh) | Cas蛋白及其应用 | |
| KR20180128864A (ko) | 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법 | |
| EP4665406A1 (en) | Crispr-transposon systems and components | |
| WO2024220135A1 (en) | Prime editing systems having pegrna with reduced auto-inhibitory interaction | |
| KR20240109203A (ko) | 레베르 유전성 시신경병증의 미토콘드리아 염기 변이 교정 시스템 | |
| CN117210435A (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| JP2025503617A (ja) | タンパク質の発現のための最適化されたポリヌクレオチド | |
| WO2025106894A1 (en) | Adenine deaminases and compositions, systems, and methods thereof | |
| CN120004994A (zh) | 一种胞嘧啶脱氨酶抑制剂SflSddi及其应用 |